Tumor News and Research

RSS

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

Helicos BioSciences and it’s collaborators will deliver presentations featured at the Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, from February 24-27, 2010.

26 Feb 2010

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

A comprehensive drug development strategy that starts with extensive screening of potential targeting agents and then narrows down to a small-molecule prototype has yielded two potential drugs that block cancer-promoting pathways in novel ways, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in two papers published back-to-back online at the Proceedings of the National Academies of Science.

26 Feb 2010

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Proton beam radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Surgeons perform nation's first incision-free myotomy procedure to treat achalasia

Surgeons at UC San Diego Medical Center have performed the nation's first incision-free myotomy, a procedure to treat achalasia, a distressing disorder which causes difficulty swallowing, regurgitation and chest pain. The innovative surgery, performed through the mouth, is the most recent in a series of groundbreaking clinical trial surgeries being evaluated by the UCSD Center for the Future of Surgery.

26 Feb 2010

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Manhattan Scientifics Inc., a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC.

26 Feb 2010

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells.

25 Feb 2010

NIPTRC and partners announce development of new imaging process for proton beam therapy in cancer

Scientists and researchers from the Northern Illinois Proton Treatment and Research Center (NIPTRC) and Northern Illinois University along with their partners are developing a new imaging process using a proton beam that they believe will be a major medical breakthrough in the delivery of proton beam therapy for cancer patients.

25 Feb 2010

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

25 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

In some states women ages 40 to 49 have less access to mammograms since the U.S. Preventive Services Task Force (USPSTF) released its recommendations to change breast cancer screening guidelines last November, according to a recent survey conducted by the Avon Foundation for Women. The USPSTF recommended changing the current mammography screening guidelines for average risk women to begin biennial screening at age 50 instead of annual mammograms starting at age 40.

24 Feb 2010

BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

BSD Medical Corporation today announced that a study titled “BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer” has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132–135) by Yang, Zhao, and Wang.

24 Feb 2010

Study may help in defining better therapeutic strategies for oral and throat cancer

Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors. Their findings from a proof-of-principle study on oral carcinomas appear in the current issue of PLoS One, the online science journal.

24 Feb 2010

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

When head and neck tumors - from sinus tumors to acoustic neuromas attached to the hearing and balance nerve at the base of the skull - are located in close proximity to such sensitive areas such as the brain and eyes, they are particularly dangerous due to possible brain injury, visionary risk or hearing loss.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

23 Feb 2010

Enzymerx completes enrollment for clinical trial of pegsitacase

EnzymeRx, LLC, a clinical-stage biotechnology company, announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase-PEG 20), and the recent launch of a second clinical study. Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

22 Feb 2010

Tumor News and Research

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Surgeons perform nation's first incision-free myotomy procedure to treat achalasia

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

NIPTRC and partners announce development of new imaging process for proton beam therapy in cancer

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

EpiCept provides business update and fourth-quarter financial highlights

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

Study may help in defining better therapeutic strategies for oral and throat cancer

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

Study shows CEL-2000 vaccine blocks RA progression in mice

Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC

Enzymerx completes enrollment for clinical trial of pegsitacase

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News